Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Study of MAPK signaling using knockout mice

Gilles Pagès1, Jacques Pouysségur

  • 1Institute of Signaling, Developmental Biology and Cancer Research, Centre Antoine Lacassagne, Nice, France.

Methods in Molecular Biology (Clifton, N.J.)
|February 3, 2004
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.

Theranostics·2026
Same author

Reply to Roesler et al. Comment on "Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. <i>Cancers</i> 2025, <i>17</i>, 3659".

Cancers·2026
Same author

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Theranostics·2026
Same author

Improving angiogenesis ameliorates the efficacy of ASO-based exon skipping for the treatment of Duchenne muscular dystrophy.

Molecular therapy. Nucleic acids·2026
Same author

Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment.

Cancers·2025
Same author

IF-CRIB: A 3D-printable device to facilitate immunofluorescence experiments and its application in screening and characterizing cells expressing a degradable form of ERK2.

Methods (San Diego, Calif.)·2025